Researchers Presented New Klotho Protein Delivery Method
A Miami conference showcased encapsulated cell technology aimed at long-term α-Klotho protein production.
Updated on Sept. 24, 2026 in Biotech
Live Poll
Do you believe new cell-based therapies will successfully improve long-term treatment for patients?
Scientists presented a novel approach to delivering the α-Klotho protein using encapsulated cell technology at the Second Annual Klotho Conference in Miami. The research explores whether these implants can provide a more sustained supply of the protein than traditional dosing methods.
Why it matters
The program seeks to address the need for consistent protein levels in patients, potentially replacing the cycle of repeated dosing. Because the research remains in its preclinical stage, it represents an early step in development that local and global health observers are watching.
The 50/50 joint venture between Avaí Bio and Austrianova has successfully completed a GMP master cell bank of genetically modified cells. This follows the formation of the partnership in 2025.
The players
Walter H. Günzburg
A professor who presented the research findings on encapsulated-cell technology at the conference.
Avaí Bio
A company that formed a 50/50 joint venture with Austrianova to pursue this research.
Austrianova
A biotechnology firm that provides the Cell-in-a-Box technology used for cell encapsulation.
Klothonova
The joint venture company formed by Avaí Bio and Austrianova to develop the delivery method.
The details
Prof. Walter H. Günzburg detailed the use of Cell-in-a-Box technology, which encapsulates cells to allow for continuous protein secretion while shielding them from the host immune system. The collaboration between Avaí Bio and Austrianova, known as Klothonova, now plans to utilize the established working cell bank to advance their process development. The technology is designed specifically to test if this implantable format improves upon the limitations of standard protein delivery.
Timeline
The Klothonova joint venture was formed in 2025.
The Second Annual Klotho Conference took place September 18-19, 2026.
The presentation outcome was announced on September 24, 2026.
Beyond the 305
This research utilizes the existing Cell-in-a-Box technology platform to explore novel therapeutic delivery. It specifically extends the application of these encapsulated systems to the delivery of α-Klotho protein, a target that has become a focus for long-term therapeutic studies.
For those interested in local biotech progress, this presentation marks a milestone in the development of the Klothonova joint venture's preclinical program. Residents should watch for further updates as the team moves from master cell banking into broader process development.
The takeaway
The presentation highlights the potential for implantable technology to simplify long-term protein therapy. Keep an eye on the development status of the Klothonova joint venture as they transition from bank preparation to the next phase of development.
Further reading
You can find more developments on local medical research on our Biotech page.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you believe new cell-based therapies will successfully improve long-term treatment for patients?
